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Abstract
Hyperglycemia is associated with abnormal plasma lipoprotein metabolism and with an elevation in circulating nucleotide
levels. We evaluated how extracellular nucleotides may act to perturb hepatic lipoprotein secretion. Adenosine diphosphate
(ADP) (.10 mM) acts like a proteasomal inhibitor to stimulate apoB100 secretion and inhibit apoA-I secretion from human
liver cells at 4 h and 24 h. ADP blocks apoA-I secretion by stimulating autophagy. The nucleotide increases cellular levels of
the autophagosome marker, LC3-II, and increases co-localization of LC3 with apoA-I in punctate autophagosomes. ADP
affects autophagy and apoA-I secretion through P2Y13. Overexpression of P2Y13 increases cellular LC3-II levels by ,50% and
blocks induction of apoA-I secretion. Conversely, a siRNA-induced reduction in P2Y13 protein expression of 50% causes
a similar reduction in cellular LC3-II levels and a 3-fold stimulation in apoA-I secretion. P2Y13 gene silencing blocks the
effects of ADP on autophagy and apoA-I secretion. A reduction in P2Y13 expression suppresses ERK1/2 phosphorylation,
increases the phosphorylation of IR-b and protein kinase B (Akt) .3-fold, and blocks the inhibition of Akt phosphorylation
by TNFa and ADP. Conversely, increasing P2Y13 expression significantly inhibits insulin-induced phosphorylation of insulin
receptor (IR-b) and Akt, similar to that observed after treatment with ADP. Nucleotides therefore act through P2Y13, ERK1/2
and insulin receptor signaling to stimulate autophagy and affect hepatic lipoprotein secretion.
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Introduction
Chronic hyperglycemia in insulin resistance is known to
increase the risk of cardiovascular disease and to be associated
with elevated plasma apoB100 and low HDL levels [1,2]. Elevated
blood glucose is also known to stimulate nucleotide secretion and
purinergic signaling [3,4]. Under stress or injury, blood and
vascular cells release nucleotides, such as ATP and ADP [5,6].
Extracellular nucleotide concentration in the bloodstream is
normally in the nM-mM range [7,8], but can increase significantly
in disease states [5,9,10]. Purinergic signaling events stimulate
mitogen-activated protein kinase (MAPK) pathways and trigger
the release of pro-inflammatory cytokines [6,11,12]. Extracellular
nucleotides thereby directly impact the development of cardiovas-
cular disease by promoting an ‘‘injury response’’ in circulating
blood cells and vascular tissues [11–13].
Extracellular nucleotides affect hepatic lipoprotein metabolism
through membrane G-protein coupled receptors (GPCR) [14,15].
Compounds that stimulate HDL secretion from the liver appear to
act through an inhibition of nucleotide signaling. Niacin has been
shown to act through GPCR pathways to stimulate the secretion of
HDL [16,17] and niacin is thought to inhibit the cellular
degradation of apoA-I through an inhibition of nucleotide
signaling [18]. We have shown that linoleic acid phospholipids
(i.e. DLPC) also act through nucleotide signaling pathways to
stimulate HDL secretion [19]. These phospholipids uniquely affect
MAPK and protein kinase B (Akt) signaling [20] to block apoA-I
degradation in liver cells [21].
Factors that stimulate or inhibit HDL secretion from the liver
appear to have the opposite effect on the secretion of the LDL
protein, apoB100. ApoB100 secretion from liver cells is regulated
by protein folding and proteasomal degradation [22,23] and
proteasomal inhibitors are known to stimulate the secretion of
apoB100 [23]. Proteasomal inhibitors also stimulate cellular
autophagic pathways [24,25]. Autophagy is an adaptive cellular
‘‘stress response’’ that promotes the lysosomal degradation of
cytosolic components when a cell is stimulated by stressors, i.e.
nutrient deprivation, extracellular signals, hormones, cytokines
and pathogens [26,27]. Autophagy is designed to protect the cell
by eliminating harmful cellular components through catabolism
and recycling. Nucleotides act much like proteasomal inhibitors to
stimulate apoB100 secretion and autophagy. The nucleotide,
adenosine diphosphate (ADP), significantly increases apoB100
secretion from liver cells and increases the levels of the autophagy
marker, microtubule-associated protein 1 light chain 3 (LC3-II).
Autophagy has been shown to be associated with cardiovascular
disease and studies suggest that excessive autophagy can lead to
cardiac hypertrophy and heart failure [28,29]. Pharmacological
intervention to regulate cellular autophagy may therefore have
therapeutic value in the treatment of cardiovascular disease.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36916This study shows that ADP acts through the specific GPCR,
P2Y13, to stimulate autophagy and block HDL secretion. While
stimulation in purinergic signaling would be expected to affect
cellular autophagy through MAPK pathways [26,30], we now
show that ADP also acts through P2Y13 to block insulin receptor
(IR-b) signaling and prevent the activation of Akt. The inhibition
of insulin signaling pathways and Akt phosphorylation are known
to stimulate autophagy [26,27]. ADP therefore stimulates
autophagy and inhibits HDL secretion by both a stimulation of
MAPK and inhibition of Akt. The study suggests that elevations in
circulating nucleotide levels in hyperglycemic states may affect
hepatic lipoprotein secretion through a stimulation in purinergic
signaling and a coordinated regulation of both proteasomal and
autophagic protein degradation.
Materials and Methods
Reagents
Dilinoleoylphosphatidylcholine (DLPC) was obtained from
Avanti Polar Lipids (Alabaster, AL). Adenosine 59-diphosphate
sodium salt (ADP), adenosine triphosphate (ATP), chloroquine
diphosphate salt as well as the PI3 kinase inhibitors, 3-
methyladenine (3-MA) and Wortmannin were purchased from
Sigma-Aldrich (Oakville, ON). The antibody to P2Y13 was
obtained from Abcam (Cambridge, MA). The LC3 polyclonal
antibody was purchased from MBL International (Woburn, MA).
Antibodies to phosphorylated ERK1/2 (p44/p42), phosphorylated
Akt (Ser473), phosphorylated mTOR (Ser2448), phosphorylated
IR-b (Tyr1345) and b-actin, as well as the mTOR inhibitor,
rapamycin, were all obtained from Cell Signaling Technology
(Danvers, MA). Human TNFa was purchased from Calbiochem
(San Diego, CA). The monoclonal antibody to human apoA-I was
purchased from Meridian Life Sciences, Inc (Saco, ME). The
antibody to apoB (1D1) was obtained from Dr. Milne and Dr.
Figure 1. Extracellular nucleotides block the induction of apoA-I secretion. HepG2 cells were pre-treated with adenosine diphosphate
(ADP) (10 to 100 mM)) for 30 min. and then incubated with 12 mM DLPC in serum-free DMEM media. (A) Conditioned media was collected after 24 h
and apoA-I concentration was quantified by ELISA. ApoA-I concentration in the media is normalized to total cell protein and expressed as mean 6 SD
of 3 independent experiments. *P,0.05 vs DLPC. (B) Conditioned media was collected after 4 h treatment with 100 mM ADP +/2 DLPC and apoA-I
concentration was quantified by ELISA. ApoA-I concentration in the media is normalized to total cell protein and expressed as mean 6 SD of 3
independent experiments. *P,0.01 vs ADP, **P,0.001 vs Control, ***P,0.001 vs DLPC. (C) Cell lysates were collected after 4 h of treatment and
apoA-I concentration was quantified by ELISA. ApoA-I concentration in the cell lysate is normalized to total cell protein and expressed as mean 6 SD
of 3 independent experiments.
doi:10.1371/journal.pone.0036916.g001
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peroxidase linked goat anti-mouse and anti-rabbit antibodies were
purchased from GE Healthcare (UK). All Stars Negative control
small interference RNA (siRNA) were purchased from Qiagen
(Mississauga, ON) and human P2Y13 siRNA were purchased from
Thermo Scientific Dharmacon (Lafayette, CO). Human P2Y13
plasmid was purchased from Origene (Rockville, MD). Inhibitors
were of analytical grade and were solubilized in dimethyl sulfoxide
(DMSO).
Cells and Cell Culture
Human hepatocarcinoma, HepG2, cells were regularly main-
tained in Dulbecco’s modified Eagle medium (DMEM) (5 g/L
glucose) containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin. Passages 4–10 were used and cells that
were 80% confluent were treated with DLPC, nucleotides and/or
inhibitors for the indicated times and concentrations under serum-
free conditions. Cell viability was evaluated after all treatment
conditions.
Preparation of DLPC Micelles
DLPC micelles were prepared in DMSO by sonication as
previously described [20]. Purity of all phospholipids was .99%.
Knockdown of Human P2Y13 by Small Interference RNA
HepG2 cells were transiently transfected with All Stars Negative
control siRNA from Qiagen (Mississauga, ON) or two different
P2Y13 siRNA sequences (ACCUUCAUCAUCUACCU-
CAAAUU or GACACUCAUGCUUCCUUUCAAUU) from
Thermo Scientific Dharmacon (Lafayette, CO), by reverse trans-
fection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in
12-well plates. In brief, complexes were prepared per manufac-
turer’s specifications with a Lipofectamine 2000-to-siRNA vol-
ume-to-mole ratio of 2:40 (mL:rmol) in 200 mL of Opti-MEM I
Reduced Serum Media (Invitrogen, Carlsbad, CA). Lipofecta-
mine-siRNA complexes were added to the cells immediately after
the cells were seeded at a density of 500,000 cells/well in a volume
of 1 mL of normal growth media containing 10% FBS in the
absence of penicillin/streptomycin. The cells were treated with
Figure 2. ADP stimulates apoB100 and apoE secretion. (A&B) HepG2 cells were incubated with 100 mM adenosine diphosphate (ADP) for
24 h in serum-free DMEM media. Conditioned media was collected and immunoblotted for apoB100 (A) and apoE (B). Histograms represent band
densitometry analysis of apoB100 or apoE, normalized to total cell protein and expressed as mean 6 SD of 3 independent experiments. *P,0.01 vs
Control. (C&D) HepG2 cells were treated with 100 mM adenosine diphosphate (ADP) or 25 mM ALLN (N-Acetyl-L-leucyl-L-leucyl-L-norleucinal) for 4 h
in serum-free DMEM media. (C) Conditioned media was collected and apoA-I concentration was quantified by ELISA. ApoA-I concentration in the
media is normalized to total cell protein and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs Control. (D) ApoB100 concentration
in the media was determined by Western blot and histograms represent band densitometry analysis of apoB100, normalized to total cell protein and
expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs Control.
doi:10.1371/journal.pone.0036916.g002
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36916Figure 3. ADP stimulates autophagy and increases cellular LC3-II. (A) HepG2 cells were treated with 100 mM adenosine diphosphate (ADP)
for 4 h in serum-free DMEM media. Cell lysates were immunoblotted for LC3. Histograms represent band densitometry analysis of LC3-I and LC3-II,
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fection. Cell media and lysate samples were harvested at the
indicated timepoints for both immunoblot and ELISA analysis.
Transfection of the control and test siRNA caused no cytotoxic
effects.
Overexpression of Human P2Y13 by Plasmid
The pCMV6 vector containing the full-length human P2Y13
cDNA was purchased from Origene (Rockville, MD). HepG2 cells
were transiently transfected with control plasmid or the pCMV6-
P2Y13 plasmid by reverse transfection using FuGENE HD (Roche
Applied Science, Laval, QC). Complexes were prepared per
manufacturer’s instructions with a FuGENE HD-to-DNA volume-
to-mass ratio of 6:2 (mlt omg) in 100 mL of Opti-MEM I Reduced
normalized to b-actin and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs Control, **P,0.001 vs Control. (B) HepG2 cells were
serum-starved (Control) or pretreated for 30 min. with 100 mM adenosine diphosphate (ADP) in serum-free DMEM media and then lysates were
harvested at the indicated timepoints (0, 3, 6 & 9 h). (Left panels) Cell lysates were immunoblotted for LC3 and b-actin. (Right panels) Cell lysates
were immunoblotted for p62 and b-actin. Blots are representative of 2 independent experiments. (C) HepG2 cells were serum-starved (Control) or
treated with 100 mM ADP in serum-free DMEM media for 4 h. Cells were fixed and permeabilized and then LC3 and apoA-I were detected by indirect
immunofluorescence using primary antibodies against human LC3 and apoA-I, and Alexa Fluor-conjugated secondary antibodies (Alexa Fluor 488
goat anti-rabbit Ab (green for LC3) and Alexa Fluor 647 anti-mouse Ab (red for apoA-I)) by confocal microscopy. Micrograph 1006and 406images of
representative cells from 2 independent experiments done in quadruplicate are shown.
doi:10.1371/journal.pone.0036916.g003
Figure 4. Increasing P2Y13 expression stimulates autophagy and blocks apoA-I secretion. HepG2 cells were transfected with either
a control pCMV plasmid (pCMV) or a pCMV plasmid expressing human P2Y13 (pCMV-P2Y13). Cell lysates were collected 48 h after transfection and
immunoblotted for P2Y13 to measure protein overexpression (Upper left panel). Histograms represent band densitometry analysis of P2Y13,
normalized to b-actin (inset A) and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs pCMV. (A) Cell lysates were immunoblotted
for LC3 and histograms represent band densitometry analysis of LC3-II, normalized to b-actin and expressed as mean 6 SD of 3 independent
experiments. *P,0.05 vs pCMV. (B) Transfected cells were treated with 100 mM ADP in serum-free DMEM media for 4 h, conditioned media was
collected and apoA-I concentration was quantified by ELISA. ApoA-I concentration in the media is normalized to total cell protein and expressed as
mean 6 SD of 3 independent experiments. *P,0.05 vs pCMV Control. (C) Transfected cells were treated with 12 mM DLPC in serum-free DMEM
media for 24 h, conditioned media was collected and apoA-I concentration was quantified by ELISA. ApoA-I concentration in the media is normalized
to total cell protein and expressed as mean 6 SD of 3 independent experiments. *P,0.01 vs pCMV Control, **P,0.01 vs pCMV+DLPC.
doi:10.1371/journal.pone.0036916.g004
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trypsinized and seeded in 12-well plates at a density of 500,000
cells/well in a volume of 1 mL in normal growth media containing
10% FBS in the absence of penicillin/streptomycin and then
50 mL of the transfection complexes were immediately added to
the suspended cells. The cells were treated with ADP, TNFa or
DLPC in serum-free DMEM 48 h after transfection. Cell media
and lysate samples were harvested at the indicated timepoints for
both immunoblot and ELISA analysis. Transfection of the control
and test plasmid caused no cytotoxic effects.
ApoA-I ELISA
ApoA-I concentration in conditioned media and cell lysate
samples were analyzed by ELISA according to manufacturer’s
instructions as previously described [20]. 96-well plates were
coated overnight with a mouse anti-human apoA-I monoclonal
antibody (Meridian Life Sciences, Inc, Saco, ME). Wells were
blocked with BSA and then samples/standards were incubated in
the wells for 2 h, followed by a 1 h incubation with a horseradish
peroxidase-linked goat anti-human apoA-I antibody. K-blue Max
TMB substrate (Neogen, Inc) was added to each well, the reaction
was stopped with 0.2 N HCl, and the absorbance was recorded at
450 nm. ApoA-I concentration in the conditioned media and cell
lysate samples were normalized to total cell protein.
Immunoblot Analysis
After treatment for the indicated timepoints, cells were washed
twice with ice-cold PBS. Cells were lysed in NP-40 lysis buffer
(Biosource, Camarillo, CA) supplemented with 1 mM PMSF and
16 protease inhibitor cocktail (Sigma, Saint Louis, MO). Cell
protein concentrations were determined by the BCA Protein Assay
(Thermo Fisher Scientific, Waltham, MA). Cell lysate samples
containing equal total protein (30 mg) were separated by SDS-
PAGE and analyzed by Western blot using specific antibodies to
apoA-I, apoB100, P2Y13, LC3, p62, p-ERK1/2, p-Akt, p-mTOR,
p-IR-b, and b-actin. Blots were exposed using the Alpha Innotech
FluorChem
TM HD Imager and band intensities were quantified
with the Alpha Ease FC
TM software.
Figure 5. Reducing P2Y13 expression blocks autophagy and stimulates apoA-I secretion. HepG2 cells were transfected with either
a negative control (si-ctrl) or a siRNA against human P2Y13. Cell lysates were collected 48 h after transfection and immunoblotted for P2Y13 to confirm
protein knockdown (Upper left panel). (A) Cell lysates were immunoblotted for LC3 and histograms represent band densitometry analysis of LC3-II,
normalized to b-actin, and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs si-Ctrl. (Inset A) Histograms represent band
densitometry analysis of P2Y13 normalized to b-actin and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs si-Ctrl. (B) Transfected
cells were treated with 100 mM ADP in serum-free DMEM media for 4 h, conditioned media was collected and apoA-I concentration was quantified by
ELISA. ApoA-I concentration in the media is normalized to total cell protein and expressed as mean 6 SD of 3 independent experiments. *P,0.05 vs
si-Ctrl, **P,0.05 vs si-P2Y13 (C) Transfected cells were treated with 12 mM DLPC in serum-free DMEM media for 24 h, conditioned media was
collected and apoA-I concentration was quantified by ELISA. ApoA-I concentration in the media is normalized to total cell protein and expressed as
mean 6 SD of 3 independent experiments. *P,0.01 vs si-Ctrl, **P,0.001 vs si-Ctrl+DLPC.
doi:10.1371/journal.pone.0036916.g005
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After treatment, the cells were fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, and then blocked in 10%
FBS for 30 min. The cells were then immunostained with 1:200
rabbit polyclonal anti-LC3 (MBL International, Woburn, MA)
and 1:200 mouse anti-apoA-I antibodies (Meridian Life Sciences,
Saco, ME) for 1 h and then with 1:1000 Alexa Fluor 488 goat anti-
rabbit IgG (H+L) and 1:1000 Alexa Fluor 647 donkey anti-mouse
IgG (H+L) (Invitrogen, Burlington, ON) for an additional 1 h.
Images were acquired on an Olympus 1X80FV1000 confocal laser
microscope using Olympus Fluoview FV1000 software and
colocalization was quantified using FV10-ASW V2.1.
Statistical Analysis
Values are shown as Mean 6 SD for at least 3 independent
experiments and P,0.05 was considered significant. Differences
between mean values were evaluated by one-way analysis of
variance (ANOVA) on ranks by a pairwise multiple comparison
using the Student-Newman-Keuls post-hoc test (SigmaStat; Systat
Software, Inc., San Jose, CA).
Results
Extracellular nucleotides inhibit hepatic apoA-I secretion
Previous work has shown that membrane ATPases control the
nucleotide-dependent endocytosis of HDL [14,31] and that
inhibition of ADP production by membrane ATPases may
promote HDL secretion [18,19]. To determine if ADP directly
affects hepatic HDL secretion, experiments were undertaken to
evaluate the effect of ADP on apoA-I secretion from liver cells. As
we have previously shown [19], dilinoleoylphosphatidylcholine
(DLPC) (12 mM) stimulates a ,4-fold increase in apoA-I secretion
(accumulation in the media) from HepG2 cells over 24 h
(Figure 1A). Pre-treatment of the cells with 20–100 mM ADP
completely blocked the induction of apoA-I secretion by DLPC
(Figure 1A). Treatment with ATP (100 mM) had a lesser effect
than ADP and only blocked the induction of apoA-I secretion by
60% (Figure S1). The effects of DLPC and ADP on apoA-I
secretion were also evident after short time periods. ADP
(100 mM) was able to significantly reduce basal apoA-I secretion
at 4 h (Figures 1B and 2C). DLPC stimulated the secretion of
apoA-I after 4 h and ADP completely blocked this DLPC-
induction of apoA-I secretion. Lower doses of ADP (25 and
50 mM) also inhibited apoA-I secretion at 4 h (not shown). ADP
treatment had no effect on cellular apoA-I levels after 4 h
(Figure 1C) or 24 h (not shown). ADP therefore significantly
reduced apoA-I mass (media+lysate) at 4 h by 20% (ADP alone) to
30% (ADP+DLPC).
Adenosine diphosphate stimulates hepatic apoB100 and
apoE secretion
Experiments were undertaken to determine if ADP might affect
the secretion of other apolipoproteins. In contrast to that observed
with apoA-I, ADP significantly increased apoB100 secretion
(Figure 2A) and apoE secretion (Figure 2B) from HepG2 cells
after 24 h. ApoB100 secretion is regulated by proteasomal
degradative pathways [22,23,32] and therefore the effect of ADP
on apolipoprotein secretion was compared to that of proteasomal
inhibitors. ADP and ALLN (25 mM) decreased apoA-I levels in the
media to a similar extent at 4 h (Figure 2C), but increased the
Figure 6. Extracellular nucleotides and P2Y13 expression regulate ERK1/2 signaling. (A) HepG2 cells were pre-treated with 12 mM DLPC
for 30 min. and then incubated with and without ADP (100 mM) for 0, 5, 15 and 30 min in DMEM serum-free media. Cell lysates were immunoblotted
for phosphorylated ERK1/2. Histograms represent densitometry analysis of p-ERK1/2 normalized to b-actin and expressed as mean percent change 6
SD of 3 independent experiments. *P,0.01 vs Ctrl, **P,0.05 vs ADP 5 min. (B) HepG2 cells were transfected with either negative control (si-Ctrl) or
P2Y13 siRNA (si-P2Y13) and incubated for 24 h. Cell lysates were immunoblotted for phosphorylated and total ERK1/2. Histograms represent band
densitometry analysis of the ratio of phospho-ERK1/2 (p-ERK1/2) to total ERK1/2 (t-ERK1/2) and are expressed as mean 6 SD for 3 independent
experiments. *P,0.05 vs. control siRNA.
doi:10.1371/journal.pone.0036916.g006
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36916Figure 7. Extracellular nucleotides and P2Y13 expression regulate insulin receptor signaling. (A) HepG2 cells were pre-treated with
12 mM DLPC for 30 min. and then incubated with and without ADP (100 mM) for 0, 5, 15 and 30 min in DMEM serum-free media. Cell lysates were
immunoblotted for phosphorylated Akt (Ser473). Histograms represent densitometry analysis of p-Akt normalized to b-actin and expressed as mean
percent change 6 SD of 3 independent experiments. *P,0.01 vs Control, **P,0.001 vs DLPC 5 min. (B) HepG2 cells were pre-treated with adenosine
diphosphate (ADP) (100 mM) or TNFa (10 ng/ml) for 5 min. and then with human insulin (100 nM) for 5 min in DMEM serum-free media. Cell lysates
were immunoblotted for phosphorylated Akt (Ser473). Histograms represent densitometry analysis of p-Akt normalized to b-actin and expressed as
mean 6 SD for 3 independent experiments. *P,0.001 vs Ctrl, **P,0.001 vs. insulin alone. (C&D) HepG2 cells were transfected with either negative
control (si-Ctrl) or P2Y13 siRNA (si-P2Y13) and incubated for 48 h. Cells were then treated with adenosine diphosphate (ADP) (100 mM) or TNFa (10 ng/
ml) for 5 min. in DMEM serum-free media. (C) Cell lysates were immunoblotted for phosphorylated insulin receptor (IR-b) (Tyr1345). Histograms
represent densitometry analysis of p-IR-b normalized to b-actin and expressed as mean 6 SD for 3 independent experiments. *P,0.01 vs si-Ctrl, **
Nucleotides, Autophagy, and HDL
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suggests that ADP may regulate apolipoprotein secretion in
a similar fashion to that observed with proteasomal inhibitors.
Adenosine diphosphate stimulates autophagy
Studies have shown that proteasomal inhibitors also act to
stimulate autophagy [24,25] and therefore experiments were
undertaken to determine if ADP affects autophagy and impacts the
level of the autophagy marker, LC3. HepG2 cells were treated
with 100 mM ADP for 4 h and then cell lysates were probed for
LC3. Figure 3A shows that ADP significantly increased both
LC3-I and LC3-II levels at 4 h. The data suggests that ADP
stimulates autophagy and this view is confirmed by the data in
Figure 3B. To determine if ADP uniquely affects the activation
versus flux of LC3 in HepG2 cells, 9 h time course studies were
undertaken. Figure 3B shows that serum starvation (control)
increases LC3-II levels in HepG2 cell lysates at 3 h, which return
to below basal levels by 9 h (left panel blots). ADP increases
LC3-II levels more quickly than the control starvation (within the
30 min pretreatment) and maintains increased cellular LC3-II
levels for 6 h (Figure 3B, left panel blots). Similar results were
seen with another autophagy marker protein, p62 (Figure 3B,
right panel blots).
Immunofluorescent experiments using laser confocal microsco-
py confirm the Western blot data and further showed that apoA-I
and LC3 are colocalized within autophagosomes. Figure 3C
(and Figure S2) illustrates 4 h confocal micrographic images of
indirect immunofluorescent stained apoA-I and LC3 in fixed and
permeabilized HepG2 cells. Control starvation conditions show
the staining pattern for both LC3 (green) and apoA-I (red) and
illustrate low levels of colocalization of the two proteins in the
merged images (yellow-orange). Similar to that shown in
Figures 3A&B, ADP increases cellular LC3 levels relative to
control, and confocal images show LC3 to be localized to punctate
autophagosomal structures within the cell (Figure 3C). When
LC3 and apoA-I immunofluorescent images for ADP treated cells
are merged, the images show significantly (P,0.001) more yellow-
orange structures in ADP-treated vs control cells (23.8%65.2% vs
7.5%63.0%), which indicates that ADP significantly increases the
colocalization of apoA-I with LC3. ADP-dependent increases in
LC3-II levels were completely inhibited by treatment with 3-
methyladenine (3-MA) (5 mM) or U0126 (10 mM), while LC3-II
levels were further increased by treatment with chloroquine
(50 mM) or Wortmannin (10 mM) (Figure S3).
P2Y13 expression affects autophagy and apoA-I secretion
Extracellular ADP affects cellular apoA-I metabolism through
the GPCR, P2Y13 [15] in hepatocytes and therefore the effect of
P2Y13 expression on autophagy and apoA-I secretion were
evaluated. Transfecting HepG2 cells with a pCMV6-P2Y13
plasmid promoted a ,50% increase in P2Y13 expression
(Figure 4, Western blot and inset) and a parallel increase in
LC3-II levels (Figure 4A). Treatment of liver cells with a pCMV6-
P2Y13 plasmid blocked the basal secretion of apoA-I at 4 h, similar
to that observed after treatment with ADP, while a combination of
pCMV6-P2Y13 and ADP had no additional effect on apoA-I
secretion (Figure 4B). Increasing P2Y13 expression in the liver
cells significantly reduced the DLPC-induction of apoA-I secretion
after 24 h (Figure 4C).
Reducing P2Y13 expression had the opposite effect. Transfect-
ing HepG2 cells with P2Y13 siRNA promoted a .50% reduction
in P2Y13 protein expression (Figure 5, Western blot and
inset) and caused a similar reduction in LC3-II levels (Figure 5A).
P2Y13 siRNA significantly stimulated apoA-I secretion at both 4 h
and 24 h (Figures 5B and 5C). After a 4 h incubation, ADP was
unable to block apoA-I secretion in cells treated with P2Y13
siRNA, but conversely, increased apoA-I secretion relative to
P2Y13 siRNA treatment alone (Figure 5B). Treatment with
DLPC (12 mM) or P2Y13 siRNA for 24 h stimulated apoA-I
secretion by ,2.5-fold, while treatment with both DLPC and
P2Y13 siRNA promoted a ,10-fold stimulation in apoA-I
secretion from HepG2 cells (Figure 5C). P2Y13 siRNA
completely blocked the effect of ADP on LC3-II (Figure S4).
Nucleotides and P2Y13 regulate MAPK signaling
Cellular autophagy is regulated by the activation of MAPK
(ERK1/2) and therefore the importance of ERK1/2 in ADP-
dependent purinergic signaling was investigated. The nucleotide,
ADP, stimulates ERK1/2 phosphorylation over a 30 min period
and DLPC blocked the activation of ERK1/2 by ADP
(Figure 6A). P2Y13 expression also affects ERK1/2 phosphory-
lation and a 50% reduction in cellular P2Y13 expression caused
a significant reduction in ERK1/2 phosphorylation after 24 h
(Figure 6B). Cell viability was unaffected by the P2Y13 siRNA.
Nucleotides and P2Y13 regulate insulin receptor signaling
Cellular autophagy is activated by the inhibition of protein
kinase B (Akt) [27]. DLPC stimulates the phosphorylation of Akt at
5 min. and ADP completely blocks the activation of Akt by DLPC
(Figure 7A). ADP also inhibits the activation of Akt by insulin.
Figure 7B shows that insulin stimulates Akt phosphorylation in
HepG2 cells and that both tumor necrosis factor a (TNFa) and
ADP inhibit insulin-induced Akt phosphorylation by ,50%.
Reducing P2Y13 expression by treatment with P2Y13 siRNA
appeared to inhibit cellular autophagic pathways by stimulating
P,0.001 vs si-Ctrl. (D) Cell lysates were also immunoblotted for phosphorylated Akt (Ser473). Histograms represent densitometry analysis of p-Akt
normalized to b-actin and expressed as mean 6 SD for 3 independent experiments.*P,0.01 vs si-Ctrl, **P,0.05 vs. si-Ctrl, ***P,0.001 vs si-Ctrl.
doi:10.1371/journal.pone.0036916.g007
Figure 8. Extracellular nucleotides act through P2Y13 to
stimulate autophagy. Elevations in blood glucose promote the
secretion and accumulation of nucleotides in the circulation. Nucleo-
tides act through P2Y13 to activate mitogenic pathways, inhibit insulin
receptor signaling and stimulate autophagic protein degradation.
Enhanced purinergic signaling in insulin resistance may give rise to
a chronic induction of cellular autophagy and a reduction in apoA-I
secretion from the liver.
doi:10.1371/journal.pone.0036916.g008
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expression significantly increases the phosphorylation of IR-b and
Akt (Figure 7C&D)b y.3-fold. P2Y13 gene silencing signifi-
cantly augmented the insulin-induced phosphorylation of Akt
(Figure S5) and blocked the inhibitory effect of TNFa and ADP
on IR-b and Akt phosphorylation (Figure 7C&D and S5).
Similar results were observed for the insulin-like growth factor
receptor (IGF-1R) (not shown). P2Y13 overexpression had the
opposite effect. Transfection of HepG2 cells with pCMV6-P2Y13
plasmid significantly reduced the phosphorylation of IR-b (Figure
S6). Increasing P2Y13 expression significantly inhibited the insulin-
induced phosphorylation of IR-b and Akt (Figure S6), similar to
that observed after treatment of HepG2 cells with ADP
(Figure 6C). P2Y13 expression significantly affected Akt phos-
phorylation, but had no effect on mTOR (Figure S7). ADP
actually increased mTOR phosphorylation, while the mTOR
inhibitor, rapamycin, significantly reduced p-mTOR levels (Fig-
ure S8).
Discussion
Insulin resistance and hyperglycemia have been shown to
perturb plasma lipoprotein metabolism and increase apoB100
levels, but decrease HDL [1,2]. Insulin resistance is consequently
a well accepted risk factor for the development of cardiovascular
disease [1]. High blood glucose levels stimulate ATP production
and promote the release of nucleotides from circulating blood cells,
endothelial cells and smooth muscle cells [3,4]. ATP is unstable in
the circulation and is quickly converted to ADP [7,8]. Elevations
in blood nucleotide levels can impact cardiovascular disease
[4,5,13] and inhibition of ADP-dependent thrombosis with P2Y12
receptor inhibitors has already shown significant cardiovascular
therapeutic value [33,34]. Niacin has also been shown to have
cardiovascular therapeutic value and this molecule appears to act
through another G-protein coupled receptor [16] to block
purinergic signaling [18] and atherogenesis [35].
Our studies show that HDL secretion is regulated similarly in
primary human hepatocytes and HepG2 liver cells and that the
linoleic acid phospholipid, dilinoleoylphosphatidylcholine (DLPC),
can stimulate HDL/apoA-I secretion [19,20,36]. DLPC appears
to act much like niacin to prevent purinergic signaling by
inhibiting F1-ATPase and blocking the production of ADP [19].
This view has been confirmed by the present work, which shows
that ADP is a potent antagonist to the induction of apoA-I
secretion by DLPC. Figure 1 shows that an [ADP] .10 mM
completely blocked the induction of apoA-I secretion by DLPC at
24 h and also at 4 h. Conversely, ADP can directly stimulate
apoB100 and apoE secretion from human liver cells at 24 h
(Figure 2A&B). The normal physiological concentration of ADP
in the bloodstream has been reported to be ,15 mM[ 8], but
elevated blood glucose levels can increase nucleotide secretion and
accumulation in the circulation [3,4]. High circulatory nucleotide
levels would therefore be expected to block hepatic apoA-I
secretion and stimulate apoB100 output. This is indeed similar to
what is thought to occur in hyperglycemic, insulin resistant
patients [1,37,38]. This may suggest that elevations in blood
nucleotide levels may be partly causative to abnormal plasma
lipoprotein levels.
Since apoB100 secretion is known to be regulated by
proteasomal degradation, we evaluated the effect of proteasomal
inhibitors on both apoB100 and apoA-I secretion. ADP and the
proteasomal inhibitor, ALLN, appear very similar and both inhibit
apoA-I secretion, but stimulate apoB100 secretion at 4 h
(Figure 2C&D). ADP may therefore act similar to proteasomal
inhibitors to stimulate autophagy [24,25]. ADP stimulates
autophagy in HepG2 cells and increases the level of autophagic
markers, LC3-I and LC3-II, and p62 over a 6 h period (Figure 3).
The ability of ADP to stimulate apoB100 secretion (Figure 2) and
increase p62 levels may indicate that ADP blocks proteasomal
degradation, since p62 levels are known to rise when the
proteasome is inhibited [26,27]. Confocal studies confirmed the
higher levels of LC3 after treatment with ADP. Micrographs
showed that LC3-II was located in punctate autophagosomes
within the liver cells and clearly showed that higher levels of LC3
and apoA-I were colocalized within autophagosomes in ADP
treated cells (Figure 3C). The view that a stimulation in
autophagy may inhibit apoA-I secretion is consistent with earlier
work, which has shown that serum deprivation, a treatment well-
known to directly stimulate autophagy (Figure 3B and [26,27]),
also inhibits apoA-I secretion of HepG2 cells by ,50% over the
first hour [39].
Human liver cells contain two ADP-receptors, P2Y1 and P2Y13,
but HDL metabolism is primarily affected by P2Y13 [15,40,41].
ADP is a potent agonist to P2Y13 and stimulates a rapid (10 min)
endocytic recycling pathway for extracellular apoA-I [14,15,31].
This recycling pathway has been shown contribute to apoA-I
lipidation, cholesterol efflux and apoE resecretion, but does not
promote significant apoA-I degradation [42–44]. Conversely, it is
known that apoA-I secretion is affected by cellular degradation
[18,21] and activation of P2Y13 appears to stimulate degradation
pathways. The direct effect of P2Y13 on both autophagy and
apoA-I secretion from human liver cells is clearly illustrated by
increasing or silencing P2Y13 gene expression. P2Y13 overexpres-
sion significantly increased cellular LC3-II levels and decreased
apoA-I secretion (Figure 4), similar to that seen with exogenous
ADP. Conversely, P2Y13 gene silencing with siRNA significantly
decreased LC3-II levels, increased both basal apoA-I secretion and
the DLPC induction in apoA-I secretion, and blocked the effects of
ADP on autophagy and apoA-I secretion (Figure S4 and
Figure 5). P2Y13 expression in HepG2 cells therefore appears to
regulate apoA-I secretion through cellular autophagic pathways.
In contrast to this work, studies in P2Y13-deficient mice have
shown that reducing P2Y13 expression caused a small reduction in
plasma HDL levels in vivo [45,46]. This may be partly due to the
fact that mice are not a human equivalent model for the study of
HDL metabolism, since numerous liver-specific signaling path-
ways differ in mice [47]. Nucleotide signaling also differs
significantly in rodents [40,48]. In studies with rat hepatocytes,
ADP acts through P2Y2 receptors to increase [IP3] and [Ca
2+]
[48]. This does not occur in human cells. Treatment of both
primary human liver cells and HepG2 cells with ADP or UDP has
no effect on cellular [IP3] and [Ca
2+] [40]. In human liver cells,
ADP stimulates MAPK and reduces [cAMP] [15,41], both of
which are known to reflect activation of P2Y13 [49,50]. We show
that ADP stimulates ERK1/2 in human liver cells (Figure 6A),
but ADP has the opposite effect in murine pancreatic cells and
inhibits ERK1/2 phosphorylation [51]. ADP and P2Y13-de-
pendent signaling may therefore be very different in humans and
rodents and this may explain why P2Y13-deficient mice show no
major lipoprotein phenotype [45,46].
Nucleotide signaling through P2Y receptors is well known to
activate MAPK pathways [49,50] and MAPK is a well-known
activator of cellular autophagy [26]. DLPC may therefore
stimulate apoA-I secretion by blocking MAPK activation and
preventing the autophagic degradation of apoA-I. DLPC can
block an ADP-dependent activation of ERK1/2 in HepG2 cells
(Figure 6A), similar to that shown in neuronal cells, where DLPC
blocked ERK1/2 activation by TNFa and hydrogen peroxide
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completely blocked the ADP-dependent increase in LC3-II levels
(Figure S3) and P2Y13-gene silencing also muted ERK1/2
activation (Figure 6B). Our data suggests that MAPK is not alone
in regulating autophagy and apoA-I secretion. ADP can block the
activation of Akt by DLPC and insulin (Figure 7A&B) and Akt is
an established inhibitor of autophagy [26,30]. Therefore, while
nucleotides may affect cellular autophagic pathways through
MAPK pathways, the insulin signaling-dependent Akt pathways
may also play an important role in the purinergic regulation of
autophagy and HDL secretion. Akt can inhibit autophagy directly,
and indirectly through mTOR [26]. Our work, however suggests
that ADP stimulates autophagy through mTOR-independent
pathways, since P2Y13 expression had no effect on mTOR
phosphorylation, while ADP increased p-mTOR levels (Figures
S7&S8).
If ADP-dependent signaling through P2Y13 impacts Akt-de-
pendent pathways, it follows that P2Y13 expression would be
expected to affect insulin receptor signaling. Consistent with this
view, a reduction in P2Y13 expression directly stimulates the
phosphorylation of IR-b and Akt by .3-fold (Figure 7), increases
insulin-dependent signaling (Figure S5) and completely blocks the
inhibition of insulin receptor signaling by TNFa and ADP
(Figure 7). Increasing P2Y13 expression has the opposite effect
and significantly inhibits insulin-induced phosphorylation of IR-
b and Akt (Figure S6). Nucleotide signaling through P2Y13 may
therefore affect insulin receptor signaling. This work appears
consistent with other studies showing that ADP acts through
P2Y13 to inhibit insulin secretion from pancreatic beta cells
[51,53].
This work shows that lipoprotein secretion and insulin signaling
pathways are affected by hepatic membrane purinergic receptor
signaling. Elevations in blood glucose promote the synthesis and
secretion of nucleotides from circulating blood cells and vascular
tissues. Nucleotides that accumulate in the circulation can then act
through purinergic receptors, i.e. P2Y13, to stimulate mitogenic
pathways and inhibit insulin receptor signaling. Enhanced
purinergic signaling in insulin resistance may give rise to an
inhibition of proteasomal degradation and a chronic induction of
cellular autophagy (Figure 8). The net result is a stimulation of
apoB100 secretion from the liver and a reduction in apoA-I
secretion. This may partly explain the well-described lipoprotein
phenotype associated with insulin resistance [1].
Supporting Information
Figure S1 ATP decrease apoA-I levels in the media at
24 h. (A) HepG2 cells were pre-treated with adenosine di-
phosphate (ADP) or adenosine triphosphate (ATP) (100 mM) for
30 min. and then incubated with 12 mM DLPC in serum-free
DMEM media. Conditioned media was collected after 24 h
treatment and apoA-I concentration was quantified by ELISA.
ApoA-I concentration in the media is normalized to total cell
protein and expressed as mean 6 SD of 3 independent
experiments *P,0.01 vs DLPC, **P,0.001 vs DLPC.
(TIF)
Figure S2 ADP stimulates autophagy. HepG2 cells were
serum-starved (Control) (A) or treated with 100 mM ADP (B)i n
serum-free DMEM media for 4 h. Cells were fixed and
permeabilized and then apoA-I and LC3 were detected by
indirect immunofluorescence using confocal microscopy. Original
images of representative micrographs at 1006magnification from
2 independent experiments performed in quadruplicate are
shown.
(TIF)
Figure S3 Effect of autophagy inhibitors on cellular
LC3-II. HepG2 cells were pre-treated with 50 mM chloroquine,
5 mM 3-methyladenine (3-MA), 10 mM wortmannin or 10 mM
U1026 for 30 min6100 mM ADP for 4 h in serum-free DMEM
media. Cell lysates were immunoblotted for LC3. Histograms
represent band densitometry analysis of LC3-II normalized to b-
actin and expressed as percent change 6 SD of 3 independent
experiments. *P,0.05 vs Control and **P,0.01 vs Control.
(TIF)
Figure S4 P2Y13 knockdown inhibits the ADP-depen-
dent stimulation in autophagy. HepG2 cells were transfected
with either negative control (si-Ctrl) or P2Y13 siRNA (si-P2Y13)
and incubated for 48 h. Cells were then incubated with ADP
(100 mM) for 4 h in DMEM serum-free media. Cell lysates were
immunoblotted for LC3 and blots are representative of 3
independent experiments.
(TIF)
Figure S5 Reducing P2Y13 expression augments insulin
receptor signaling. HepG2 cells were transfected with either
negative control (si-Ctrl) or P2Y13 siRNA (si-P2Y13) and in-
cubated for 48 h. Cells were then pre-incubated with ADP
(100 mM) for 5 min. and then with human insulin (100 nM) for
5 min in DMEM serum-free media. Cell lysates were immuno-
blotted for phosphorylated Akt (Ser473). Histograms represent
densitometry analysis of p-Akt normalized to b-actin and
expressed as mean percent change 6 SD for 2 independent
experiments.*P,0.05 vs si-Ctrl, **P,0.01 vs si- P2Y13.
(TIF)
Figure S6 P2Y13 overexpression blocks insulin receptor
signaling. HepG2 cells were transfected with either a control
pCMV plasmid (pCMV) or a pCMV plasmid expressing human
P2Y13 (pCMV-P2Y13). Cell lysates were collected 48 h after
transfection and immunoblotted for P2Y13 to measure protein
overexpression (inset, panel A). Cells were then treated with
human insulin (100 nM) for 5 min in DMEM serum-free media.
Cell lysates were immunoblotted for insulin receptor (p-IR-b)( A)
and phosphorylated Akt (Ser473) (B). Histograms represent
densitometry analysis normalized to b-actin and are expressed as
mean percent change 6 SD for 3 independent experiments.
(A)*P,0.001 vs pCMV and **P,0.01 vs pCMV+Insulin. (B)
*P,0.001 vs pCMV and ** P,0.05 vs pCMV+Insulin.
(TIF)
Figure S7 Reducing P2Y13 expression had no effect on
the phosphorylation of mTOR. HepG2 cells were transfected
with either a negative control (si-ctrl) or a siRNA against human
P2Y13. Cell lysates were collected 48 h after transfection and
immunoblotted for phosphorylated Akt (Ser473) and phosphory-
lated mTOR (Ser2448). Histograms represent densitometry
analysis of p-Akt and p-mTOR normalized to b-actin and
expressed as mean 6 SD of 3 independent experiments.
*P,0.001 vs si-Ctrl.
(TIF)
Figure S8 ADP increases mTOR phosphorylation.
HepG2 cells were treated with 100 mM ADP or 250 nM
rapamycin for 4 h. Cell lysates were immunoblotted for phos-
phorylated mTOR (Ser2448). Histograms represent densitometry
analysis of p-mTOR normalized to b-actin and expressed as mean
percent change 6 SD of 3 independent experiments. *P,0.05 vs
control.
(TIF)
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